Timothy Francis Cloughesy MD
Neurooncology
Professor of Neuology/Director, UCLA NeuroOncology Program
Join to view full profile
710 Westwood Plaza1-230 RNRCLos Angeles, CA 90095
Phone+1 310-825-5321
Fax+1 310-825-5321
Dr. Cloughesy is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Timothy Cloughesy is a neurologist specializing in neuro-oncology, based in Los Angeles, CA. He completed his neurology residency at UCLA David Geffen School of Medicine/UCLA Medical Center after earning his medical degree from Tulane University School of Medicine. Dr. Cloughesy has extensive experience in neuro-oncology and has authored several publications on glioblastoma and glioma in reputed journals. He is involved in clinical trials focusing on innovative treatments for glioblastoma. Over his career, Dr. Cloughesy has received numerous accolades, including being named one of America's Top Doctors and recognized for his contributions to cancer treatment.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1988 - 1991
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1987 - 1988
Tulane University School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1988 - 2028
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- America's Top Doctors Castle Connolly, 2002-2014
Clinical Trials
Publications & Presentations
PubMed
- Influence of Post-Bolus Acquisition Duration on Estimated Percentage of Signal Recovery from Dynamic Susceptibility Contrast MRI in Brain Tumors.Gianluca Nocera, Francesco Sanvito, Jingwen Yao, Irina Kryukov, Antonella Castellano
AJNR. American Journal of Neuroradiology. 2026-11-03 - 1 citationsAutomated imaging response evaluation system: Prototype software tool for standardized radiographic response assessment in glioblastoma clinical trials.Ashley Teraishi, Francesco Sanvito, Catalina Raymond, Nicholas S Cho, Jason Norris
Neuro-Oncology Practice. 2026-10-01 - Imaging patterns of necrosis after treatment with chemoradiation are prognostic for survival in glioblastoma.Johanna Heugenhauser, Francesco Sanvito, Jingwen Yao, Irina Kryukov, Catalina Raymond
European Radiology. 2026-09-29
Press Mentions
IDH Inhibitor Activity in Brain Cancer Persists with Longer Follow-UpNovember 24th, 2024- Global Coalition for Adaptive Research Announces Evaluation of AZD1390 in GBM AGILE TrialNovember 23rd, 2024
- Mew Precision Medicine Approach Predicts Glioblastoma Response to TherapyNovember 22nd, 2024
Grant Support
- Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaUNIVERSITY OF CALIFORNIA LOS ANGELES2022–2027
- Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastomaUNIVERSITY OF CALIFORNIA LOS ANGELES2022–2027
- UCLA IRB 08-09-042: Phase I Trial Of Aflibercept (Vegf Trap) With Radiation TheNational Center For Research Resources2010
- UCLA IRB # 06-04-104 "A Phase I/II, Dual-Center, Open-Label Trial Of The SAFENational Center For Research Resources2009–2010
- UCLA IRB # 06-04-016 "Phase II Trial Of Bevacizumab In Combination With TemozNational Center For Research Resources2007–2010
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
